RxDoctor Payments DataLook up a doctor →

Jeffrey Davis, MD

Urology · Wichita, KSNPI 1073773008

Payments from drug & device makers

$7,511in general payments, 2019–2025

Across 292 payments — averaging $25.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$1K
  • Johnson & Johnson$668
  • Dendreon Pharmaceuticals LLC$580
  • Pfizer$374
  • Merck$318
  • Astellas Pharma US Inc$297
  • plus $4K from 39 others
$355in research payments, 2019–2025

Across 1 payment — averaging $355.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$355

What the payments were for

  • Travel & lodging$77410%
  • Food & beverage$6,47786%
  • Education$2613%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,511 in reported general payments places this provider in the 75th percentile of 111 urology providers in Kansas.

See all urology providers in Kansas

Medicare billing

Part B allowed, 2024
$417,841
Medicare patients
1,359
Services billed
13,176

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix154$397,316
XtandiEnzalutamide21$266,188
ErleadaApalutamide18$263,695
NubeqaDarolutamide11$151,491
MyrbetriqMirabegron191$100,419
GemtesaVibegron97$72,439
Tamsulosin Hcl886$8,567
Solifenacin Succinate195$7,110
Fesoterodine Fumarate ErFesoterodine Fumarate62$6,420
Finasteride464$4,423
NitrofurantoinNitrofurantoin Macrocrystal52$2,063
Potassium Citrate ErPotassium Citrate45$1,915
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst83$1,874
Methenamine Hippurate27$1,842
Silodosin24$1,732

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$92$469,755251 claims
Astellas Pharma US IncXtandi, Myrbetriq$297$366,607212 claims
Johnson & JohnsonErleada$668$263,69518 claims
BayerNubeqa$226$151,49111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 111 urology providers in Kansas.

Other urology in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →